|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Pathophysiology/Complications |
Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
Variations with increasing levels of HbA1c
1 Department of Metabolism, Lapeyronie Hospital, Montpellier, France
2 University Institute of Clinical Research, Montpellier, France
OBJECTIVE—The exact contributions of postprandial and fasting glucose increments to overall hyperglycemia remain controversial. The discrepancies between the data published previously might be caused by the interference of several factors. To test the effect of overall glycemic control itself, we analyzed the diurnal glycemic profiles of type 2 diabetic patients investigated at different levels of HbA1c.
RESEARCH DESIGN AND METHODS—In 290 non–insulin- and non–acarbose-using patients with type 2 diabetes, plasma glucose (PG) concentrations were determined at fasting (8:00 A.M.) and during postprandial and postabsorptive periods (at 11:00 A.M., 2:00 P.M., and 5:00 P.M.). The areas under the curve above fasting PG concentrations (AUC1) and >6.1 mmol/l (AUC2) were calculated for further evaluation of the relative contributions of postprandial (AUC1/AUC2, %) and fasting [(AUC2 - AUC1)/AUC2, %] PG increments to the overall diurnal hyperglycemia. The data were compared over quintiles of HbA1c.
RESULTS—The relative contribution of postprandial glucose decreased progressively from the lowest (69.7%) to the highest quintile of HbA1c (30.5%, P < 0.001), whereas the relative contribution of fasting glucose increased gradually with increasing levels of HbA1c: 30.3% in the lowest vs. 69.5% in the highest quintile (P < 0.001).
CONCLUSIONS—The relative contribution of postprandial glucose excursions is predominant in fairly controlled patients, whereas the contribution of fasting hyperglycemia increases gradually with diabetes worsening. These results could therefore provide a unifying explanation for the discrepancies as observed in previous studies.
Abbreviations: AUC, area under the curve • AUC1, AUC above fasting PG concentrations • AUC2, AUC >6.1 mmol/l • CGMS, continuous glucose monitoring system • CV, coefficient of variation • PG, plasma glucose.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  L. F Van Gaal, S. W Gutkin, and M. A Nauck Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur. J. Endocrinol., June 1, 2008; 158(6): 773 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dickinson, D. P Hancock, P. Petocz, A. Ceriello, and J. Brand-Miller High-glycemic index carbohydrate increases nuclear factor-{kappa}B activation in mononuclear cells of young, lean healthy subjects Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1188 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yang, Q. Ji, D. Zhu, J. Yang, L. Chen, Z. Liu, D. Yu, and L. Yan Biphasic Insulin Aspart 30 Three Times Daily Is More Effective Than a Twice-Daily Regimen, Without Increasing Hypoglycemia, in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Drugs Diabetes Care, May 1, 2008; 31(5): 852 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Kruger Exploring the Pharmacotherapeutic Options for Treating Type 2 Diabetes The Diabetes Educator, May 1, 2008; 34(Supplement_3): 60S - 65S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dagdelen, L. L. Ilag, S. Martin, S. J. Jacober, R. R. Holman, A. J. Farmer, M. J. Davies, G. T. McMahon, and R. G. Dluhy Addition of insulin to oral therapy in type 2 diabetes. N. Engl. J. Med., March 13, 2008; 358(11): 1197 - 1198. [Full Text] [PDF]
|
|
|
|
|
|
D. Giugliano, A. Ceriello, and K. Esposito Glucose metabolism and hyperglycemia Am. J. Clinical Nutrition, January 1, 2008; 87(1): 217S - 222S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mita, H. Watada, T. Shimizu, Y. Tamura, F. Sato, T. Watanabe, J. B. Choi, T. Hirose, Y. Tanaka, and R. Kawamori Nateglinide Reduces Carotid Intima-Media Thickening in Type 2 Diabetic Patients Under Good Glycemic Control Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2456 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. McMahon and R. G. Dluhy Intention to Treat -- Initiating Insulin and the 4-T Study N. Engl. J. Med., October 25, 2007; 357(17): 1759 - 1761. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Holman, K. I. Thorne, A. J. Farmer, M. J. Davies, J. F. Keenan, S. Paul, J. C. Levy, and the 4-T Study Group Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes N. Engl. J. Med., September 21, 2007; (2007) NEJMoa075392v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Marrs and J. J. Saseen Which patients are candidates for dipeptidyl peptidase IV inhibitors? Am. J. Health Syst. Pharm., June 15, 2007; 64(12): 1261 - 1261. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]
|
|
|
|
|
|
E. von Kriegstein, K. von Kriegstein, C. A. Guevara, J. L. Gross, R. I. Henkin, G. T. McMahon, and R. A. Arky Inhaled Insulin for Diabetes Mellitus N. Engl. J. Med., May 17, 2007; 356(20): 2106 - 2108. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Garg On Real-Time Estimates of Blood Glucose Levels: Response to Trevino Diabetes Care, May 1, 2007; 30(5): e35 - e36. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zinman, B. J. Hoogwerf, S. Duran Garcia, D. R. Milton, J. M. Giaconia, D. D. Kim, M. E. Trautmann, and R. G. Brodows The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A Randomized Trial Ann Intern Med, April 3, 2007; 146(7): 477 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Jellinger, H. E. Lebovitz, J. A. Davidson, and on behalf of the ACE/AACE Outpatient Glycemic Cont Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al. Diabetes Care, April 1, 2007; 30(4): e16 - e17. [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Childs, N. C. Kesty, E. Klein, R. Rubin, and A. Wick Considering Pramlintide Therapy for Postprandial Blood Glucose Control Diabetes Spectr, April 1, 2007; 20(2): 108 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Kruger Tying It All Together: Matching Insulin Regimens to Individual Patient Needs The Diabetes Educator, April 1, 2007; 33(Supplement_4): 91S - 95S. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Gavin III An Uncompromising Approach to Achieving Glycemic Goals The Diabetes Educator, March 1, 2007; 33(Supplement_3): 52S - 59S. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Gavin III Practical Approaches to Insulin Therapy The Diabetes Educator, March 1, 2007; 33(Supplement_3): 66S - 73S. [Full Text] [PDF]
|
|
|
|
|
|
L. Monnier, C. Colette, G. J. Dunseath, and D. R. Owens The Loss of Postprandial Glycemic Control Precedes Stepwise Deterioration of Fasting With Worsening Diabetes Diabetes Care, February 1, 2007; 30(2): 263 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Kruger, S. L. Aronoff, and S. V. Edelman Through the Looking Glass: Current and Future Perspectives on the Role of Hormonal Interplay in Glucose Homeostasis The Diabetes Educator, February 1, 2007; 33(Supplement_2): 32S - 46S. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Abrahamson A 74-Year-Old Woman With Diabetes JAMA, January 10, 2007; 297(2): 196 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Parkin and J. A. Davidson Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al. Diabetes Care, January 1, 2007; 30(1): 192 - 193. [Full Text] [PDF]
|
|
|
|
|
|
S. Garg and L. Jovanovic Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values: Safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor Diabetes Care, December 1, 2006; 29(12): 2644 - 2649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ceglia, J. Lau, and A. G. Pittas Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med, November 7, 2006; 145(9): 665 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Glycemic treatment in type 1 and type 2 diabetes. Diabetes Care, November 1, 2006; 29(11): 2549 - 2555. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lucotti, E. Setola, L. D. Monti, E. Galluccio, S. Costa, E. P. Sandoli, I. Fermo, G. Rabaiotti, R. Gatti, and P. Piatti Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E906 - E912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Edelman, S. Garg, J. Frias, D. Maggs, Y. Wang, B. Zhang, S. Strobel, K. Lutz, and O. Kolterman A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes Diabetes Care, October 1, 2006; 29(10): 2189 - 2195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Meformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea: Response to Mikhail and Cope Diabetes Care, October 1, 2006; 29(10): 2333 - 2334. [Full Text] [PDF]
|
|
|
|
|
|
A. Stirban, M. Negrean, B. Stratmann, T. Gawlowski, T. Horstmann, C. Gotting, K. Kleesiek, M. Mueller-Roesel, T. Koschinsky, J. Uribarri, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care, September 1, 2006; 29(9): 2064 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rave, O. Klein, A. D. Frick, and R. H.A. Becker Advantage of Premeal-Injected Insulin Glulisine Compared With Regular Human Insulin in Subjects With Type 1 Diabetes Diabetes Care, August 1, 2006; 29(8): 1812 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Gerich Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk. The Diabetes Educator, July 1, 2006; 32(4): 513 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes Diabetes Care, July 1, 2006; 29(7): 1486 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Droumaguet, B. Balkau, D. Simon, E. Caces, J. Tichet, M. A. Charles, E. Eschwege, and the DESIR Study Group Use of HbA1c in Predicting Progression to Diabetes in French Men and Women: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) Diabetes Care, July 1, 2006; 29(7): 1619 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hood, V. Valentine, S. Mac, and W. H Polonsky Use of Exenatide in Patients With Type 2 Diabetes Diabetes Spectr, July 1, 2006; 19(3): 181 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Dungan, J. B. Buse, J. Largay, M. M. Kelly, E. A. Button, S. Kato, and S. Wittlin 1,5-Anhydroglucitol and Postprandial Hyperglycemia as Measured by Continuous Glucose Monitoring System in Moderately Controlled Patients With Diabetes. Diabetes Care, June 1, 2006; 29(6): 1214 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, P. Home, and on behalf of the Levemir Treat-to-Target Study Gro A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care, June 1, 2006; 29(6): 1269 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gentilcore, R. Chaikomin, K. L. Jones, A. Russo, C. Feinle-Bisset, J. M. Wishart, C. K. Rayner, and M. Horowitz Effects of Fat on Gastric Emptying of and the Glycemic, Insulin, and Incretin Responses to a Carbohydrate Meal in Type 2 Diabetes J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2062 - 2067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Davis and S. M. Renda Treating to Target in Type 2 Diabetes: A Case Presentation. The Diabetes Educator, June 1, 2006; 32(Supplement_4): 137S - 145S. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Owen Amylin Replacement Therapy in Patients With Insulin-Requiring Type 2 Diabetes The Diabetes Educator, May 1, 2006; 32(Supplement_3): 105S - 110S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.-P. Cristol, and C. Colette Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes JAMA, April 12, 2006; 295(14): 1681 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Saudek, R. L. Derr, and R. R. Kalyani Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A1c JAMA, April 12, 2006; 295(14): 1688 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Drucker Incretin-based therapies: a clinical need filled by unique metabolic effects. The Diabetes Educator, March 1, 2006; 32(2 Suppl): 65S - 71S. [Full Text] [PDF]
|
|
|
|
 |
|
 M Horowitz and M A Nauck To be or not to be--an incretin or enterogastrone? Gut, February 1, 2006; 55(2): 148 - 150. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]
|
|
|
|
|
|
J. Meece Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes The Diabetes Educator, January 1, 2006; 32(1): 9S - 18S. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wittlin Treating the Spectrum of Type 2 Diabetes: Emphasis on Insulin Pump Therapy The Diabetes Educator, January 1, 2006; 32(1): 39S - 46S. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Heine, L. F. Van Gaal, D. Johns, M. J. Mihm, M. H. Widel, R. G. Brodows, and for the GWAA Study Group* Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial Ann Intern Med, October 18, 2005; 143(8): 559 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Erion, P. D. van Poelje, Q. Dang, S. R. Kasibhatla, S. C. Potter, M. R. Reddy, K. R. Reddy, T. Jiang, and W. N. Lipscomb MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes PNAS, May 31, 2005; 102(22): 7970 - 7975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Hirsch, R. M. Bergenstal, C. G. Parkin, E. Wright Jr., and J. B. Buse A Real-World Approach to Insulin Therapy in Primary Care Practice Clin. Diabetes, April 1, 2005; 23(2): 78 - 86. [Full Text] [PDF]
|
|
|
|
 |
|
 The Proper Time for Insulin Treatment DOC News, March 1, 2005; 2(3): 5 - 5. [Full Text]
|
|
|
|
|
|
P. Raskin, E. Allen, P. Hollander, A. Lewin, R. A. Gabbay, P. Hu, B. Bode, A. Garber, and for the INITIATE Study Group Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs Diabetes Care, February 1, 2005; 28(2): 260 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ceriello, D. Johns, M. Widel, D. J. Eckland, K. J. Gilmore, and M. H. Tan Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes Diabetes Care, February 1, 2005; 28(2): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Davidson Starting Insulin Therapy in Type 2 Diabetic Patients: Does it really matter how? Diabetes Care, February 1, 2005; 28(2): 494 - 495. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ceriello Postprandial Hyperglycemia and Diabetes Complications: Is It Time to Treat? Diabetes, January 1, 2005; 54(1): 1 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|